Publication Details

Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease.

Gerson LB, Huff FJ, Hila A, Hirota WK, Reilley S, Agrawal A, Lal R, Luo W, Castell D. Am J Gastroenterol. 2010; 105 (6): 1266-75

Arbaclofen placarbil (AP), previously designated as XP19986, is an investigational prodrug of the active R-isomer of baclofen, a gamma-aminobutyric acid agonist reflux inhibitor. The aim of this study was to assess the efficacy and safety of AP for decreasing meal-induced reflux episodes in patients with gastroesophageal reflux disease (GERD).

PubMedID: 20040914